Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 20:13:898192.
doi: 10.3389/fimmu.2022.898192. eCollection 2022.

Role of COVID-19 Vaccines in SARS-CoV-2 Variants

Zhou Zhou  1   2   3 , Yimiao Zhu  1   3 , Ming Chu  1
Affiliations
Review

Role of COVID-19 Vaccines in SARS-CoV-2 Variants

Zhou Zhou et al. Front Immunol. .

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a threat to the health of the global population. As the result of a global effort in the determination of origin, structure, and pathogenesis of SARS-CoV-2 and its variants, particularly such the variant of concern as Delta Variant and Omicron Variant, the understanding of SARS-CoV-2 are deepening and the development of vaccines against SARS-CoV-2 are ongoing. Currently, AstraZeneca-Vaxzevria/SII-Covishield vaccine, Janssen-Ad26.COV2.S vaccine, Moderna-mRNA-1273 vaccine, Pfizer BioNTech-Comirnaty vaccine and Sinovac-CoronaVac vaccine have been listed as WHO Emergency Use Listing (EUL) Qualified Vaccines by WHO. Because of the antigen escape caused by the mutation in variants, the effectiveness of vaccines, which are currently the main means of prevention and treatment, has been affected by varying degrees. Herein, we review the current status of mutations of SARS-CoV-2 variants, the different approaches used in the development of COVID-19 vaccines, and COVID-19 vaccine effectiveness against SARS-CoV-2 variants.

Keywords: COVID-19; COVID-19 vaccines; Delta variant; Omicron variant; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The structure and genome organization of SARS-CoV-2. (A) Four structural proteins in SARS-CoV-2 are the spike (S), envelope (E), nucleocapsid (N) and membrane (M). S, E and M are embedded in the lipid bilayer envelope while RNA are coated by N. (B) The genome of SARS-CoV-2 consists of 13-15 open reading frames and encodes protein which plays important role in binding and translation between the virus and the host cell.
Figure 2
Figure 2
Timeline of Pfizer BioNTech-Comirnaty vaccine, AstraZeneca-Vaxzevria vaccine, Moderna-mRNA-1273 vaccine, Janssen-Ad26.COV 2.S vaccine and Sinovac-CoronaVac vaccine listed in WHO EUL recommendation.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) . WHO Coronavirus (COVID-19) Dashboard (2021). Available at: https://covid19.who.int/.
    1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A Pneumonia Outbreak Associated With a New Coronavirus of Probable Bat Origin. Nature (2020) 579(7798):270–3. doi: 10.1038/s41586-020-2012-7 - DOI - PMC - PubMed
    1. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM Structure of the 2019-Ncov Spike in the Prefusion Conformation. Science (2020) 367(6488):1260–3. doi: 10.1126/science.abb2507 - DOI - PMC - PubMed
    1. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). In: StatPearls. Treasure Island (FL: StatPearls Publishing; (2022). - PubMed
    1. World Health Organization (WHO) . COVID-19 Vaccine Tracker and Landscape (2021). Available at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand....

Publication types

Supplementary concepts